



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/823,866	04/14/2004	Lawrence J. Stern	07917-212001 / UMMC 03-10	6194
26161 7590 05/12/2009 FISH & RICHARDSON PC P.O. BOX 1022 MINNEAPOLIS, MN 55440-1022			EXAMINER JUNG, UNSU	
			ART UNIT 1641	PAPER NUMBER
			NOTIFICATION DATE 05/12/2009	DELIVERY MODE ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Office Action Summary	Application No. 10/823,866	Applicant(s) STERN ET AL.	
	Examiner UNSU JUNG	Art Unit 1641	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on 22 January 2009.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-14, 16, 20, 25-36, 38-50 and 52-57 is/are pending in the application.
- 4a) Of the above claim(s) 10, 14, 26-36, 38-50 and 52-57 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-9, 11-13, 16, 20 and 25 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 14 April 2004 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Response to Amendment

1. Applicant's amendments in the reply filed on January 22, 2009 have been acknowledged and entered. The reply included amendments to claims 1, 3, 4, 26, 34, 55, and 56.

Status of Claims

2. As a preliminary matter, claim 16 has been inadvertently left out of claims under pending and consideration in the previous Office Action dated July 22, 2008 (see PTOL-326 form and item 3). This inadvertent error has been corrected in the current Office Action.

3. Claims 1-14, 16, 20, 25-36, 38-50, and 52-57 are pending, claims 10, 14, 26-36, 38-50, and 52-57 have been withdrawn from consideration, and claims 1-9, 11-13, 16, 20, and 25 are currently under consideration for patentability under 37 CFR 1.104.

Rejections Withdrawn

4. The following rejections have been withdrawn in view of amended claims 1, 3, and 4 in the reply filed on April 28, 2008:

- Rejection of claims 1, 2, 5, 11, 12, 16, 20, and 25 under 35 U.S.C. 103(a) as being unpatentable over Webb et al. (WO 97/46256, Dec. 11, 1997) in

Art Unit: 1641

view of Rhode et al. (U.S. Patent No. 6,232,445, May 15, 2001), Lehmann et al. (U.S. Patent No. 5,939,281, Aug. 17, 1999), and Wagner et al. (U.S. Patent No. 6,329,209 B1, Dec. 11, 2001);

- Rejection of claims 3, 4, 6, and 7 under 35 U.S.C. 103(a) as being unpatentable over Webb et al. (WO 97/46256, Dec. 11, 1997) in view of Rhode et al. (U.S. Patent No. 6,232,445, May 15, 2001), Lehmann et al. (U.S. Patent No. 5,939,281, Aug. 17, 1999), and Wagner et al. (U.S. Patent No. 6,329,209 B1, Dec. 11, 2001), and further in view of Taylor (U.S. Patent No. 6,103,479, Aug. 15, 2000);
- Rejection of claims 8 and 9 under 35 U.S.C. 103(a) as being unpatentable over Webb et al. (WO 97/46256, Dec. 11, 1997) in view of Rhode et al. (U.S. Patent No. 6,232,445, May 15, 2001), Lehmann et al. (U.S. Patent No. 5,939,281, Aug. 17, 1999), and Wagner et al. (U.S. Patent No. 6,329,209 B1, Dec. 11, 2001), and further in view of Tom-Moy et al. (U.S. Patent No. 6,235,488, May 22, 2001); and
- Rejection of claim 13 under 35 U.S.C. 103(a) as being unpatentable over Webb et al. (WO 97/46256, Dec. 11, 1997) in view of Rhode et al. (U.S. Patent No. 6,232,445, May 15, 2001), Lehmann et al. (U.S. Patent No. 5,939,281, Aug. 17, 1999), and Wagner et al. (U.S. Patent No. 6,329,209 B1, Dec. 11, 2001), and further in view of Abraham et al. (*J. Immunol.*, 20014, Vol. 167, pp5193-5201) and Mikesell et al. (U.S. PG Pub. No. US 2002/0095024, Filed on June 6, 2001).

New Grounds of Rejections

Claim Rejections - 35 USC § 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

7. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to

Art Unit: 1641

consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

8. Claims 1-7, 11, 12, 16, 20, and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Webb et al. (WO 97/46256, Dec. 11, 1997) in view of Rhode et al. (U.S. Patent No. 6,232,445, May 15, 2001), Lehmann et al. (U.S. Patent No. 5,939,281, Aug. 17, 1999), Yurino et al. (U.S. Patent No. 6,127,125, Oct. 3, 2000), and Alfenito (U.S. Patent No. 6,355,419 B1, Mar. 12, 2002).

Webb et al. teaches an array (see entire document) comprising a substrate (support, p49, lines 7-18) and a plurality of MHC molecules complexed with antigen-derived peptides (p18, lines 9-17 and p50, line 1-p51, line 25) immobilized in spatially distinct areas on the substrate (wells of microtiter plates, p80, lines 24-31). Webb et al. further teaches that activation of T-cells is characterized by proliferation of the responsive T cell population coordinated with the selective production of cytokines (p16, lines 28-32). With respect to claim 20, Webb et al. teaches that the different cytokine profiles such as IL-2, IL-4, IL-5, IL-10, and IFN- γ characterize functional phenotypes of type 1 and type 2 T-cells (p16, lines 8-23).

With respect to claims 11 and 12, Webb et al. teaches an array, further comprising costimulatory molecules immobilized in the spatially-distinct areas on the substrate (p49, lines 7-14), wherein the costimulatory molecules are costimulatory antibodies (p21, line 27-p22, line 6).

With respect to claim 16, Webb et al. teaches an array, wherein the MHC molecules comprise class II MHC molecules (p18, lines 20-30).

However, Webb et al. is silent on disclosing that the each group of spatially distinct areas comprises a plurality of different MHC-peptide complexes and that the array, further comprises anti-factor antibodies specific for secreted factors, immobilized spatially-distinct areas on the substrate. Webb et al. further fails to teach that the substrate is flat. Finally, Webb et al. fails to teach that at least one hydrophobic barrier surrounds a plurality of the spatially-distinct areas and each of the spatially-distinct areas is not surrounded individually by a separate hydrophobic barrier, such that when a single volume of sample is applied inside of the at least one hydrophobic barrier, all areas in the plurality of said spatially-distinct areas are in contact with the single volume of sample.

With respect to claims 1 and 2, Rhode et al. teaches that MHC complexes can be used to screen immune cells such as T-cells expressing a desired target structure in vitro (see entire document, particularly column 4, lines 24-26). A wide variety of peptides can be presented for interaction with T-cells (i.e. a library of different peptides can be linked to a MHC molecule for presentation of T-cells, column 5, lines 11-17).

With respect to claim 5, Rhode et al. further teaches that an array of MHC complexes can be formed on a substrate such as 96-well plates (column 55, lines 45-51) and MHC molecules are selected from Class I MHC molecules, Class II MHC molecules, or Class I and Class II MHC molecules (column 3, lines 36-45).

With respect to claims 1 and 25, Lehmann et al. teaches a method of detecting secreted cytokines by activated T-cells using cytokine capture assay (see entire document, particularly, column 3, lines 14-36). The cytokine capture assay of Lehmann et al. involves plating both the activating molecules (test antigen peptide) co-incubated with immobilized cytokine capture antibodies (column 3, lines 14-36).

With respect to claim 1, Yurino et al. teaches a biochip comprising a plurality of regions bound with various probes (see entire document, particularly Abstract). The biochip has a flat upper surface of a generally equal height. As a result, a sample can be applied to the entire features of the biochip (column 6, lines 48-60).

With respect to claims 6 and 7, Yurino et al. teaches a substrate comprising glass (column 6, lines 48-60), which is optically transparent.

Alfenito teaches an array of probes comprising a nylon membrane; a plurality of subarrays of probes on the nylon membrane, the subarrays comprising a plurality of individual spots wherein each spot is comprised of a plurality of probes of the same sequence; and a plurality of hydrophobic barriers located between the subarrays on the nylon membrane, whereby the plurality of hydrophobic barriers prevents cross contamination between adjacent subarrays (see entire document, particularly column 3, lines 5-14). Many samples may be interrogated as pools at the same subarrays or independently with different subarrays within one support (column 35, lines 55-63).

Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention to employ plurality of different MHC-peptide complexes of Rhode et al., which are formed by a MHC molecule complexed with a library of different peptides,

in the array of Webb et al. in order to screen T cells expressing a desired target structure in vitro. The advantage of screening T cells for their interaction with a plurality of different peptides complexed to a MHC molecule provides the motivation to combine teachings of Webb et al. and Rhode et al. with a reasonable expectation of success.

In addition, it would have been obvious to one of ordinary skill in the art at the time of the invention to include anti-factor antibodies specific for secreted factors co-immobilized on the spatially-distinct areas of the substrate with activating molecules as taught by Lehmann et al. in the array of Webb et al. in order to perform cytokine capture assay for detecting secreted cytokines by the activated T-cells. The advantage of allowing T-cell activation and capturing of the secreted cytokines following the activation in the same area of the substrate provides the motivation to combine teachings of Webb et al. and Lehmann et al. with a reasonable expectation of success as the use of co-immobilized MHC molecules complexed with antigen-derived peptides and anti-factor antibodies specific for secreted factors would eliminate additional steps of supernatant harvesting and transferring of the supernatant to another substrate for cytokine detection assay necessary to determine cytokine profile of the activated T-cell populations.

Further, it would have been obvious to one of ordinary skill in the art at the time of the invention to employ the flat surface for the protein microarrays of Webb et al. in view of Rhode et al. and Lehmann et al. as taught by Yurino et al. in order to apply a sample to all the features of the protein microarray. The ease of applying sample to desired regions of the protein microarray provides the motivation to combine teachings

Art Unit: 1641

of Webb et al. in view of Rhode et al. and Lehmann et al. and Yurino et al. with a reasonable expectation of success. In addition, because both flat and non-flat substrates be used to provide support for the protein arrays, it would have been obvious to one of ordinary skill in the art at the time of the invention to substitute the multi-well plate format of Webb et al. in view of Rhode et al. and Lehmann et al. for the flat substrate format of Yurino et al. to achieve to predictable result of providing a suitable support for the protein array.

Finally, it would have been obvious to one of ordinary skill in the art at the time of the invention to provide at least one hydrophobic barrier surrounding a plurality of the spatially-distinct areas (each of the spatially-distinct areas is not surrounded individually by a separate hydrophobic barrier) such that when a single volume of sample is applied inside of the at least one hydrophobic barrier, all areas in the plurality of said spatially-distinct areas are in contact with the single volume of sample as taught by Alfenito in the array of Webb et al. in view of Rhode et al., Lehmann et al., and Yurino et al. in order to prevent cross contamination between adjacent subarrays for simultaneous analysis of multiple samples. The advantage of analyzing multiple samples simultaneously with cross contamination provides the motivation to combine teachings of Webb et al. in view of Rhode et al., Lehmann et al., and Yurino et al. and Alfenito with a reasonable expectation of success.

With respect to claim 1 and all dependent claims thereof, the recitation that spatially-distinct areas are configured to allow contact with one sample at essentially the same time and with the same sample is not a positive limitation but only requires the

Art Unit: 1641

ability to so perform. It does not constitute a limitation in any patentable sense. *In re Hutchison*, 69 USPQ 138 (CCPA 1946); *In re Swinehart*, 169 USPQ 226 (CCPA 1971); and *In re Schreiber*, 44 USPQ2d 1429 (Fed. Cir. 1997). A patent applicant is free to recite features of an apparatus either structurally or functionally. See *In re Swinehart*, 439 F.2d 210, 212, 169 USPQ 226, 228 (CCPA 1971) (“ [T]here is nothing intrinsically wrong with [defining something by what it does rather than what it is] in drafting patent claims.”). Yet, choosing to define an element functionally, i.e., by what it does, carries with it a risk. As our predecessor court stated in *In re Swinehart*, 439 F.2d at 213, 169 USPQ at 228:

where the Patent Office has reason to believe that a functional limitation asserted to be critical for establishing novelty in the claimed subject matter may, in fact, be an inherent characteristic of the prior art, it possesses the authority to require the applicant to prove that the subject matter shown to be in the prior art does not possess the characteristic relied on

Therefore, the feature of “the spatially-distinct areas are configured to allow contact with one sample at essentially the same time and with the same sample” would be an inherent characteristic of the array of Webb et al. in view of Rhode et al., Lehmann et al., Yurino et al., and Alfenito since the array of Webb et al. in view of Rhode et al., Lehmann et al., Yurino et al., and Alfenito meets all the structural limitations of the claimed array.

With respect to claims 3 and 4, Yurino et al. teaches that an entire array can be used to assay a plurality of different analytes in a single sample as set forth above. Given the teachings of Yurino et al., it would have been obvious to one of ordinary skill in the art at the time of the invention to provide a hydrophobic barrier surrounding all of

Art Unit: 1641

the spatially distinct areas on the array substrate in order to simultaneously analyze analytes that may be present in a single sample binding to probes on all the spatially distinct areas of the array. The advantage of assaying parallel for plurality of different analytes in a sample provides the motivation to provide a hydrophobic barrier surrounding all of the spatially distinct areas on the array substrate with a reasonable expectation of success. Further, Webb et al. in view of Rhode et al., Lehmann et al., Yurino et al., and Alfenito discloses the claimed invention except for a single hydrophobic barrier surrounding all of the spatially distinct areas. It would have been obvious to one of ordinary skill in the art at the time of the invention to arrange a hydrophobic barrier surrounding all of the spatially distinct areas, since it has been held that rearranging parts of an invention involves only routine skill in the art. *In re Japikse*, 181 F.2d 1019, 86 USPQ 70 (CCPA 1950).

9. Claims 8 and 9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Webb et al. (WO 97/46256, Dec. 11, 1997) in view of Rhode et al. (U.S. Patent No. 6,232,445, May 15, 2001), Lehmann et al. (U.S. Patent No. 5,939,281, Aug. 17, 1999), Yurino et al. (U.S. Patent No. 6,127,125, Oct. 3, 2000), and Alfrenito (U.S. Patent No. 6,355,419 B1, Mar. 12, 2002) as applied to claim 1 above, and further in view of Tom-Moy et al. (U.S. Patent No. 6,235,488, May 22, 2001).

Webb et al. in view of Rhode et al., Lehmann et al., Yurino et al., and Alfenito teaches an array comprising a substrate and an array of MHC molecules complexed with antigen-derived peptides and costimulatory antibodies immobilized in spatially

Art Unit: 1641

distinct areas on the substrate as set forth above. Webb et al. in view of Rhode et al., Lehmann et al., Yurino et al., and Alfenito further teaches that biotinylated MHC molecules can be immobilized on the avidin-coated substrate via biotin-avidin linked interactions with the substrate (p81, lines 10-16). However, Webb et al. in view of Rhode et al., Lehmann et al., Yurino et al., and Alfenito fails to teach that streptavidin can be used in place of avidin.

With respect to claims 8 and 9, Tom-Moy et al. teaches that streptavidin can be a substitute for avidin since it has similar biotin-binding properties (see entire document, particularly column 4, lines 62-63).

Therefore, Webb et al. in view of Rhode et al., Lehmann et al., Yurino et al., and Alfenito meets the limitations of claims 8 and 9 except that it employs avidin rather than streptavidin to coat the substrate surface for immobilization of biotinylated MHC molecules. However, because these two elements were art-recognized equivalents at the time of the invention in the specific binding applications as taught by Tom-Moy et al., where it is immaterial whether the avidin or streptavidin is used to bind to a biotin, one of ordinary skill in the art at the time of the invention would have found it obvious to substitute streptavidin for the avidin of Webb et al. in view of Rhode et al., Lehmann et al., Yurino et al., and Alfenito.

10. Claim 13 is rejected under 35 U.S.C. 103(a) as being unpatentable over Webb et al. (WO 97/46256, Dec. 11, 1997) in view of Rhode et al. (U.S. Patent No. 6,232,445, May 15, 2001), Lehmann et al. (U.S. Patent No. 5,939,281, Aug. 17, 1999), Yurino et al.

Art Unit: 1641

(U.S. Patent No. 6,127,125, Oct. 3, 2000), and Alfrenito (U.S. Patent No. 6,355,419 B1, Mar. 12, 2002) as applied to claims 1, 11, and 12 above, and further in view of Abraham et al. (*J. Immunol.*, 20014, Vol. 167, pp5193-5201) and Mikesell et al. (U.S. PG Pub. No. US 2002/0095024, Filed on June 6, 2001).

Webb et al. in view of Rhode et al., Lehmann et al., Yurino et al., and Alfenito teaches an array comprising a substrate and an array of MHC molecules complexed with antigen-derived peptides and costimulatory antibodies immobilized in spatially distinct areas on the substrate as set forth above. Webb et al. further teaches the costimulatory molecules include ICAM's (ICAM-1, ICAM-2, and ICAM-3, p72, line 14-p74, line 20). Activation of T cells is characterized by proliferation of the responsive T cell population coordinated with the selection of cytokines (p16, lines 28-32). However, Webb et al. in view of Rhode et al., Lehmann et al., Yurino et al., and Alfenito fails to teach an array, wherein the costimulatory antibodies bind specifically to CD11a.

Abraham et al. teaches that integrin LFA-1 serves as an accessory molecule in T cell activation (see entire document). The primary pathway whereby engagement of LFA-1 through its ligand ICAM-1 up-regulates IL-2 gene expression through enhanced IL-2 transcription (Abstract). Further, a number of anti-LFA-1 Abs has agonist/costimulatory activity such as anti-CD11a mAb (p5197, right column).

Mikesell et al. teaches that a first signal mediated by foreign antigens presented by MHC complexes causes T-cell entry into the cell cycle and a second signal, termed costimulation, causes cytokine production and T-cell proliferation (p1, paragraph [0003]).

Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention to include anti-CD11a antibody of Abraham et al. as a costimulatory antibodies in the array of Webb et al. in view of Rhode et al., Lehmann et al., Yurino et al., and Alfenito in order to provide costimulatory signal in addition to the antigenic signal of the MHC molecules complexed with antigen-derived peptides necessary for production of cytokines and T-cell proliferation, which can be used to detect T-cell activation/responsiveness. The advantage of delivering necessary costimulatory signal for T-cell characterization provides the motivation to combine teachings of Webb et al. in view of Rhode et al., Lehmann et al., Yurino et al., and Alfenito and Abraham et al. with a reasonable expectation of success as Mikesell et al. teaches that a first signal mediated by foreign antigens presented by MHC complexes causes T-cell entry into the cell cycle and a second signal, termed costimulation, causes cytokine production and T-cell proliferation.

Further, Webb et al. et al. in view of Rhode et al., Lehmann et al., Yurino et al., and Alfenito meets the limitations of claim 13 except that it employs an ICAM's rather than anti-CD11a antibodies as costimulatory molecules. However, because these two elements were art-recognized equivalents at the time of the invention in the T-cell immunology arts, where it is immaterial whether the ICAM's or anti-CD11a antibodies are used to provide costimulatory signal to T-cells, one of ordinary skill in the art at the time of the invention would have found it obvious to substitute anti-CD11a antibodies for the ICAM's of Webb et al. in view of Rhode et al., Lehmann et al., Yurino et al., and Alfenito.

Response to Arguments

11. Applicant's arguments with respect to claims 1-14, 16, 20, and 25 have been considered but are moot in view of the new ground(s) of rejection.

Since the prior art fulfills all the limitations currently recited in the claims, the invention as currently recited would read upon the prior art.

Conclusion

12. No claim is allowed.

13. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

14. Any inquiry concerning this communication or earlier communications from the examiner should be directed to UNSU JUNG whose telephone number is (571)272-8506. The examiner can normally be reached on M-F: 9-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mark Shibuya can be reached on 571-272-0806. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Unsu Jung/
Unsu Jung
Primary Examiner
Art Unit 1641